Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response
Abstract Aim: To identify molecular mechanisms and predictors of response to aromatase inhibitors (AIs) in primary ER+ breast cancer. Background: Although AIs are highly effective suppressants of estrogen synthesis in postmenopausal women, up to 50% of patients derive little or no clinical benefit f...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 70; no. 24_Supplement; pp. S2 - S2-5 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
15.12.2010
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Aim: To identify molecular mechanisms and predictors of response to aromatase inhibitors (AIs) in primary ER+ breast cancer. Background: Although AIs are highly effective suppressants of estrogen synthesis in postmenopausal women, up to 50% of patients derive little or no clinical benefit from AI treatment. The proliferation marker Ki67 provides a valuable pharmacodynamic marker for response in the presurgical setting and 2 week measurements of this marker have been shown to predict recurrence-free survival1. However, understanding of the precise molecular effects of AIs and causes of resistance is limited. We present, to our knowledge, the largest study of the transcriptional effects of AI treatment in the neoadjuvant setting.
Methods: Baseline and 2wk post-treatment core-cut tumor biopsies were obtained from 112 postmenopausal women with stage I to IIIB ER+ early breast cancer who received single agent neoadjuvant anastrozole2. RNA extracted from biopsies was analysed on Illumina 48K microarrays. Genes which changed expression upon anastrozole treatment were identified using paired class comparison of the 81 matched baseline and 2wk pairs from which gene expression data was available. Correlates of response were determined using multiple testing corrected Spearman correlation analysis. Pathway analysis was performed on the ranked list of correlated genes. IHC for Ki67, ER and PgR was performed centrally on FFPE sections from duplicate core biopsies.
Results: At a false discovery rate (FDR) of 0.01, 1154 genes were differentially expressed (792 down-regulated and 362 up-regulated). Proliferation-associated genes and classical estrogen-dependent genes such as TOP2A, CCNB2, TFF1, and PDZK1 were strongly downregulated (FDR<1x10-7). Upregulated genes included collagens and chemokines such as COL16A1 and CCL14. Pathway analysis revealed cell cycle, estrogen receptor and apoptosis-related pathways to be amongst the most significantly altered (P<0.005). However, the response of all genes upon treatment varied considerably between patients. Investigation of genes expressed in pre-treatment biopsies which correlated with response to AI as measured by the decrease in Ki67 over two weeks revealed a strong inflammatory signature. Higher expression of pro-inflammatory genes such as TNF, CXCR3 and IL2RA was associated with poorer response, while expression of GATA3 was associated with more favourable response (P<0.001). Multivariable analysis revealed that the relationship of TNF with response was independent of estrogen receptor expression. Conclusions: Consistent with the variable clinical benefit from AI treatment, the molecular response to AI treatment shows substantial hetereogeneity. Poor Ki67 response to anastrozole treatment is associated with higher baseline expression of an inflammatory signature. Further evaluation of this signature has the potential to identify patients who would benefit from additional therapies.
1. Dowsett et al., JNCI, 2007, 99, 167-70.
2. Smith et al., JCO, 2007, 3816-22.
Supported by the Mary-Jean Mitchell Green Foundation and Breakthrough Breast Cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr S2-5. |
---|---|
AbstractList | Abstract
Aim: To identify molecular mechanisms and predictors of response to aromatase inhibitors (AIs) in primary ER+ breast cancer. Background: Although AIs are highly effective suppressants of estrogen synthesis in postmenopausal women, up to 50% of patients derive little or no clinical benefit from AI treatment. The proliferation marker Ki67 provides a valuable pharmacodynamic marker for response in the presurgical setting and 2 week measurements of this marker have been shown to predict recurrence-free survival1. However, understanding of the precise molecular effects of AIs and causes of resistance is limited. We present, to our knowledge, the largest study of the transcriptional effects of AI treatment in the neoadjuvant setting.
Methods: Baseline and 2wk post-treatment core-cut tumor biopsies were obtained from 112 postmenopausal women with stage I to IIIB ER+ early breast cancer who received single agent neoadjuvant anastrozole2. RNA extracted from biopsies was analysed on Illumina 48K microarrays. Genes which changed expression upon anastrozole treatment were identified using paired class comparison of the 81 matched baseline and 2wk pairs from which gene expression data was available. Correlates of response were determined using multiple testing corrected Spearman correlation analysis. Pathway analysis was performed on the ranked list of correlated genes. IHC for Ki67, ER and PgR was performed centrally on FFPE sections from duplicate core biopsies.
Results: At a false discovery rate (FDR) of 0.01, 1154 genes were differentially expressed (792 down-regulated and 362 up-regulated). Proliferation-associated genes and classical estrogen-dependent genes such as TOP2A, CCNB2, TFF1, and PDZK1 were strongly downregulated (FDR<1x10-7). Upregulated genes included collagens and chemokines such as COL16A1 and CCL14. Pathway analysis revealed cell cycle, estrogen receptor and apoptosis-related pathways to be amongst the most significantly altered (P<0.005). However, the response of all genes upon treatment varied considerably between patients. Investigation of genes expressed in pre-treatment biopsies which correlated with response to AI as measured by the decrease in Ki67 over two weeks revealed a strong inflammatory signature. Higher expression of pro-inflammatory genes such as TNF, CXCR3 and IL2RA was associated with poorer response, while expression of GATA3 was associated with more favourable response (P<0.001). Multivariable analysis revealed that the relationship of TNF with response was independent of estrogen receptor expression. Conclusions: Consistent with the variable clinical benefit from AI treatment, the molecular response to AI treatment shows substantial hetereogeneity. Poor Ki67 response to anastrozole treatment is associated with higher baseline expression of an inflammatory signature. Further evaluation of this signature has the potential to identify patients who would benefit from additional therapies.
1. Dowsett et al., JNCI, 2007, 99, 167-70.
2. Smith et al., JCO, 2007, 3816-22.
Supported by the Mary-Jean Mitchell Green Foundation and Breakthrough Breast Cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr S2-5. |
Author | Dunbier, AK Anderson, H Ghazoui, Z Smith, IE Dowsett, M. |
Author_xml | – sequence: 1 givenname: AK surname: Dunbier fullname: Dunbier, AK – sequence: 2 givenname: Z surname: Ghazoui fullname: Ghazoui, Z – sequence: 3 givenname: H surname: Anderson fullname: Anderson, H – sequence: 4 givenname: IE surname: Smith fullname: Smith, IE – sequence: 5 givenname: M. surname: Dowsett fullname: Dowsett, M. |
BookMark | eNo9kM1OwzAQhC1UJNrCKyC_gIud2GnKLS1_lVpRkXK2nGQNRold2c6BOw9OIipOq1nNjEbfDE2ss4DQLaMLxkR-RynNieDLZFEW603JKCkTIi7QlIk0J0vOxQRN_01XaBbC1yAFo2KKfooqRK_qiMfQPd67Fuq-VR4fvNOmNfYDO40L7zoVVQC8tZ-mMtF5cvSgIjT44EIke7DupPqgWrwe_iHiY9-53ge8bcBGow0E_AARfGessjGMrW8QTs4GuEaXWrUBbs53jt6fHo-bF7J7fd5uih2p2bCXiEpV2UrrJFcqT3hDK-C00RkDSCkAqzmvV022oqrmSZOwIQW8UiAU5bpZVukcZX-9tXcheNDy5E2n_LdkVI4s5YhJjpjkmaUsEynSX9e_bUA |
CitedBy_id | crossref_primary_10_1007_s12609_011_0056_2 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/0008-5472.SABCS10-S2-5 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | S2-5 |
ExternalDocumentID | 10_1158_0008_5472_SABCS10_S2_5 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 3O- 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AFFNX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 UDS W2D W8F WH7 WOQ XJT YKV YZZ |
ID | FETCH-LOGICAL-c1005-5bab69ff28aa824d0be40df61ee30ee1c44c9d690ac42d21c10e4bae5a04fd7b3 |
ISSN | 0008-5472 |
IngestDate | Thu Sep 26 16:53:00 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 24_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1005-5bab69ff28aa824d0be40df61ee30ee1c44c9d690ac42d21c10e4bae5a04fd7b3 |
ParticipantIDs | crossref_primary_10_1158_0008_5472_SABCS10_S2_5 |
PublicationCentury | 2000 |
PublicationDate | 2010-12-15 |
PublicationDateYYYYMMDD | 2010-12-15 |
PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-15 day: 15 |
PublicationDecade | 2010 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2010 |
SSID | ssj0005105 |
Score | 2.0206926 |
Snippet | Abstract
Aim: To identify molecular mechanisms and predictors of response to aromatase inhibitors (AIs) in primary ER+ breast cancer. Background: Although AIs... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | S2 |
Title | Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response |
Volume | 70 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiKd4ywduVbqJ6yQ2t-yysAsqB9KV9hbZjq1WKi3qJpc98_f4T4xj59FSIZZLVEXyJMp8Hc-Mv5lB6N2UK6OmpQmETCFAkTINRFKKIBXMdmeRXHNbKDz7mpxf0s9X8dVo9GvAWqorOVE3B-tK_kercA_0aqtkb6HZTijcgN-gX7iChuH6TzrOpE1UqGqcQ6hnY_tZO-zWFgCY5cpTmrPtBhxT2K_AHCyWEv7E22BuvUXwNu203mCm1xA819egrxPLUq_G8_o7vMH12BXyGoinwTTtMme-OXrtfrMDpbdj30Jo0ZwRO7JHY4xWq8kg9QDOs1z6adpdtvXTQtxs6uXOoUnWVOA4fkB3tNXlhC7OhqkLRwNxxZudOWZBTN3snonuLXBKXY_J1kS72SIeioQWzcTTnhrkbG9OBru4_e6Hd4iYOUqle_Ikz05Oc3i1dsFuS-69rbIjMDahU8zs0T0rrJzCyylyUsR30F2S8tjmAj5cfOkZR55R2z7bF6yDnOPD7zPwlQZOz_wheuCjFZw56D1CI71-jO7NPB_jCfrZIhBbQe9xhz_c4Q9vDO7wh__AH97DH3b4wx5_uMcfHuLPSm3x9xRdfjybn54Hfq5HoCLb-DaWQibcGMKEYISWodQ0LE0SaT0NtY4UpYqXCQ-FoqQkEazSVAodi5CaMpXTZ-hovVnr5whHkTBUKyOEYbRMiODSsFhyxsGzpwl_gY7bL1j8cO1bir_r7uWtV7xC93twv0ZH1bbWb8BTreTbRv-_AQk4khc |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+S2-5%3A+Molecular+Profiling+of+Aromatase+Inhibitor-Treated+Post-Menopausal+Breast+Tumours+Identifies+Determinants+of+Response&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Dunbier%2C+AK&rft.au=Ghazoui%2C+Z&rft.au=Anderson%2C+H&rft.au=Smith%2C+IE&rft.date=2010-12-15&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=70&rft.issue=24_Supplement&rft.spage=S2&rft.epage=S2-5&rft_id=info:doi/10.1158%2F0008-5472.SABCS10-S2-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_0008_5472_SABCS10_S2_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |